Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$155.04 USD

155.04
7,145,777

-0.43 (-0.28%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $155.14 +0.10 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Sunesis Offers Updates on SNS-062 and Qinprezo Programs

Sunesis (SNSS) provided updates on two of its lead programs: SNS-062, and Qinprezo (vosaroxin).

    Can AbbVie (ABBV) Spring a Surprise This Earnings Season?

    AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.

      Mark Vickery headshot

      Q4 Earnings Roundup: JNJ, VZ, MMM, DD, Etc.

      Ahead of the opening bell today, we have plenty of Q4 earnings results to report.

        J&J (JNJ) Q4 Earnings Top; Seeks Options for Diabetes Unit

        Johnson & Johnson (JNJ) reported a mixed quarter with earnings beating expectations while sales missing the same.

          The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies

          The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies

            J&J (JNJ) Beats on Q4 Earnings, Sales Miss; Stock Down

            JNJ beat on fourth quarter earnings - the company reported EPS of $1.58 while our consensus called for EPS of $1.56.

              Tracey Ryniec headshot

              The Best Earnings Charts on the Street

              It's not easy to beat on earnings every quarter for years but these companies are doing it.

                Swarup Gupta headshot

                Dow Stocks to Watch for Earnings on Nov 24: DD, JNJ, TRV, VZ

                The nature of these releases is likely to determine the fortunes of the Dow in the days ahead.

                  Sweta Killa headshot

                  Can Q4 Earnings Revitalize Healthcare ETFs?

                  The Q4 earnings could bring some near-term relief given that the sector is expected to post earnings growth of 2.9% and revenue growth of 5.6%.

                    5 Best Performing Healthcare Mutual Funds of 2016

                    Investors rely on the healthcare firms to safeguard their investments as demand for its services does not vary much with market conditions

                      J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio

                      Ethicon Endo-Surgery, Inc. a subsidiary of Johnson & Johnson (JNJ), announced the acquisition of Megadyne Medical Products, Inc., a privately held medical device company.

                        What's in Store for Abbott Labs (ABT) This Earnings Season?

                        Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.

                          Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication

                          AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

                            What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?

                            Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.

                              Madeleine Johnson headshot

                              Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment

                              After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.

                                Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults

                                Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.

                                  Neena Mishra headshot

                                  5 ETF Investment Ideas for 2017

                                  We have highlighted some ETF areas that are likely to shine in 2017.

                                    Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study

                                    Bristol-Myers (BMY) and GeneCentric Diagnostics inked an exploratory biomarker research collaboration.

                                      Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)

                                      Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.

                                        The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic

                                        The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic

                                          Pfizer's Humira Biosimilar Meets Primary Endpoint in Study

                                          Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.

                                            Bristol-Myers, J&J Ink Immunotherapy Research Collaboration

                                            Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.

                                              Lilly Jardiance Family Diabetes Drugs' Label to be Updated

                                              Eli Lilly & Company (LLY) recently announced that the FDA has approved the inclusion of data from the EMPA-REG OUTCOME study on the labels of three type 2 diabetes medicines belonging to the Jardiance family ??? Synjardy, Synjardy XR and Glyxambi.

                                                Company News for January 03, 2017

                                                Companies In The News are: MYL,JNJ,GPOR,PBR,S,TMUS

                                                  Mylan (MYL) Announces Multiple Generic Launches in the U.S.

                                                  Mylan (MYL) announced quite a few generic launches in the U.S. in Dec 2016.